Physician profile
Bernard Gran
NPI 1285602078
$19,112.22
in general payments reported to CMS, 2019-2025
78 companies · $2,572 in 2025
The $2,572 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $2,294 · 2021: $2,963 · 2022: $2,231 · 2023: $3,409 · 2024: $3,222 · 2025: $2,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,176 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,176.36 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,122.41 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $2,145.57 | 2020-2025 | |
| Amgen INC. | $1,178.77 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $838.54 | 2019-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $792.49 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Eisai INC. | $613.60 | 2019-2025 | |
| Adamas Pharmaceuticals, INC. | $591.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $589.58 | 2019-2025 | |
| Lilly USA, LLC | $573.47 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Tanabe Pharma America, INC. | $380.70 | 2019-2025 | Radicava |
| Almatica Pharma LLC | $370.87 | 2021-2023 | Gralise |
| Acorda Therapeutics, INC | $349.66 | 2019-2024 | Inbrija |
| Lundbeck LLC | $287.99 | 2020-2025 | Vyepti, Rexulti |
| Pfizer INC. | $285.36 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $281.97 | 2020-2025 | Acthar |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Gran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.